A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

This feasibility study (n=0, withdrawn) aimed to assess the combination of clinician-directed cognitive behavioural therapy (CBT) supplemented with the Mindset app alongside esketamine therapy in individuals with treatment-resistant depression.

The trial, sponsored by Janssen Research & Development, LLC, explored the potential of this combined approach to addressing depression. It was set to take place at various locations in the United States, including Yale University, Rush University Medical Center, the University of Chicago, Sheppard Pratt Health System, and the University of Cincinnati.

Unfortunately, the study was withdrawn due to budget constraints and a shift in research priorities away from this investigation.

Topic Treatment-Resistant Depression Depression
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Johnson & Johnson
One of the largest pharmaceutical companies in the world, Johnson & Johnson are responsible for bringing esketamine to market in the form of Spravato.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.